Development of a New Validated RP-HPLC Method for Simultaneous Estimation and Stability Study of Tegafur, Gimeracil and Oteracil in Combined Dosage Form

ABSTRACT

Aim: This study developed a validated and stability-analyzing Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) method for simultaneous determination of selected drugs Materials and Methods: Separation, quantification and degradation of the selected drugs and their degradation study was performed on Waters Alliance-e2695, with X Bridge phenyl column (150×4.6 mM, 3.5 μ) column, mixture of Acetonitrile (ACN) and 0.1% v/v trifluoroacetic acid (50:50% v/v) as mobile phase, flow rate of 1.0 mL/min at 244 nm under ambient temperature using PDA detector. Results:Tegafur, Gimeracil and Oteracil were separated effectively with retention times of 2.8, 7.5 and 9.5 min respectively. The optimized method was validated in different aspects as per the ICH Q1A(R2) guidelines. The method showed linear responses at 50-300 μg/mL (r2=0.99984), 14.50-87 μg/mL (r2=0.99930) and 39.50-237.00 μg/mL (r2=0.99980) for tegafur, gimeracil and oteracil, respectively. Results of inter- and intraday, robustness analysis in terms of %RSD were found to be less than 2.0%. Forced degradation analysis indicated that most of the forced degradation conditions induced impurities in the selected drugs, except for hydrolysis degradation. Conclusion: The results indicate that the method conditions are aligned with the ICH method validation limits. The forced degradation study results indicated that except in hydrolytic degradation, the drugs were degraded to produce impurities. Therefore, the developed method may be suitable for the simultaneous determination of the selected drugs in routine analysis.

KEYWORDS

• Gimeracil
• Oteracil
• RP-HPLC
• Simultaneous
• Stability studies
• Tegafur

Showing references and in-text citations exactly as published.

• DOI10.5530/ijper.20265079Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPER.

• Article · VOLUME 60, ISSUE 1SThe Role of EPAC in the Pathogenesis of Cardiovascular Complications: A ReviewNandini Dubey, Vishal Kumar Vishwakarma, Aanchal Verma, Ahsas Goyal, Harlokesh Narayan Yadav · pp. s1–s10Research ArticleSame type: Article
• Article · VOLUME 60, ISSUE 1SGlobal Comparison of Gene and Cell Therapy Regulations: A Cross-Regional Analysis of FDA, EMA, TGA, CSFDA, DCGI, PMDA, IFDA and MFDSSeyed Heidar Mohammadi, Gholamhossein Sadeghian, Hoseein Shomali, Mohamadreza Abedi, Behrooz Jannat, Faham Khamesipour · pp. s18–s32Research ArticleSame type: Article
• Article · VOLUME 60, ISSUE 1SReview on Exploring the Combination Effect of Aldosterone along with Plasma Renin with Melatonin and Hydro-Cortisol in Diurnal RhythmMainak Pal, Masud Sk, Saheli Mandal, Dipanjan Mandal · pp. s33–s41Research ArticleSame type: Article
• Article · VOLUME 60, ISSUE 1SRegulatory Pathway for Genotoxic Impurities in Europe, US, Canada, India, Australia and UKKavyashree Kadehalli Ramegowda, Sangita Mishra, Venkatesh Madhugiri Prakash · pp. s42–s51Research ArticleSame type: Article